Role of - Azilsartan - Azilsartan/ chlorthalidone

1. Role of- Azilsartan- Azilsartan/chlorthalidone

2. Azilsartan • Azilsartan Medoximil (AZL-M) is the prodrug of a potent and selective Angiotensin Receptor blocker (ARB) undergoing development for the treatment of hypertension

3. Azilsartan efficacy: Change From Baseline in 24-h Mean BP at Week 6 SBP* DBP† AZL-M 40 mg AZL-M80 mg Valsartan320 mg Olmesartan40 mg AZL-M 40 mg AZL-M 80 mg Valsartan320 mg Olmesartan40 mg Placebo Placebo Change in BP (mm Hg) ‡ ‡ ‡ ‡§ ‡ ‡§|| ‡¶ ‡§|| Baseline: 144.30-146.33 mm Hg Baseline: 87.58-90.14 mm Hg *Primary endpoint †Secondary endpoint ‡P<0.001 vs placebo §P≤0.001 vsvalsartan 320 mg ||P≤0.011 vsolmesartan 40 mg ¶P=0.020 vsvalsartan 320 mg White WB, et al. Hypertension. 2011;57(3):413-20

4. Azilsartan efficacy: Change From Baseline in Clinic BP at Week 6 SBP* DBP† AZL-M 40 mg AZL-M 80 mg Valsartan320 mg Olmesartan 40 mg AZL-M 40 mg AZL-M 80 mg Valsartan320 mg Olmesartan 40 mg Placebo Placebo Change in BP (mm Hg) ‡ ‡ ‡ ‡ ‡¶ ‡§|| ‡§|| ‡§|| Baseline: 91.91-93.66 mm Hg Baseline: 156.32-157.95 mm Hg *Key secondary endpoint † Secondary endpoint ‡P<0.001 vs placebo §P<0.020 vsolmesartan 40 mg ||P<0.001 vsvalsartan 320 mg ¶P=0.017 vsvalsartan 320 mg White WB, et al. Hypertension. 2011;57(3):413-20

5. Azilsartan: Change in Trough Sitting Clinic SBP* Week 6 Week 10 0 AZL-M/CLD AZL-M+HCTZ -10 -20 -29.5 -30 -32.8 -35.1 -37.8 -40 † † Baseline values were 164.70.55 mm Hg and 164.40.56 mm Hg Data are least-squares mean±SE *Primary endpoint †P<0.001 Bakris et al. Results of a double-blind randomized study comparing CLD and HCTZ combined with the new ARB Azilsartan Medoxomil in primary HTN. Late breaking Clinical Trial session presented at: American Society of Hypertension Annual Scientific Meeting and Exposition; 2010 May 1-4; NYC, NY

6. Sustained efficacy at each hour over 24 hours in a 6-week studyAzilsartan-M vsOlmesartan-M and Valsartan White et al. The New Angiotensin Receptor Blocker Azilsartan Medoxomil Has Superior 24-Hour Blood Pressure-Lowering Efficacy to Both Olmesartan and Valsartan. Poster session presented at: American Society of Hypertension Annual Scientific Meeting and Exposition; 2010 May 1-4; NYC,NY

7. Change in SBP by ABPMCLD vs. HCTZ on background of AZL-M Week 6 Week 10 0 Baseline 146.5± 0.89 Baseline 145.4± 0.88 Baseline 146.5± 0.89 Baseline 145.4± 0.88 AZL-M–CLD AZL-M + HCTZ -10 a P<0.001 -20 -19.9 -22.4 -25.7a -30 -26.6a Change in Mean 24-Hour SBP (mmHg) by ABPM Data are least-squares mean ± SE. Bakris et al. Results of a double-blind randomized study comparing CLD and HCTZ combined with the new ARB Azilsartan Medoxomil in primary HTN. Late breaking Clinical Trial session presented at:: American Society of Hypertension Annual Scientific Meeting and Exposition; 2010 May 1-4; NYC,NY